NFKB1 and prostate carcinoma: While the interaction with PAFR leads to NF-κB activation and consequently induction of COX and prostaglandins to a pro-inflammatory process and cell resistance37, a PPAR-γ agonist may induce prostate cancer growth inhibition39.